What is the recommended treatment for Cryptococcal (CCM) Meningitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Cryptococcal Meningitis

The recommended treatment for cryptococcal meningitis is induction therapy with amphotericin B deoxycholate (0.7-1.0 mg/kg/day) plus flucytosine (100 mg/kg/day) for 2 weeks, followed by fluconazole (400 mg/day) for 8 weeks as consolidation therapy, and then fluconazole (200 mg/day) for maintenance. 1, 2

Treatment Approach Based on Patient Population

HIV-Infected Patients

  • Induction Phase (First 2 weeks):

    • First-line: Amphotericin B deoxycholate (0.7-1.0 mg/kg/day IV) plus flucytosine (100 mg/kg/day orally in 4 divided doses) for 2 weeks 1, 2
    • For renal concerns: Liposomal amphotericin B (3-4 mg/kg/day) or ABLC (5 mg/kg/day) plus flucytosine 1
    • For flucytosine-intolerant patients: Amphotericin B alone for 4-6 weeks 1
  • Consolidation Phase (Next 8 weeks):

    • Fluconazole 400 mg daily 1, 3
  • Maintenance Phase:

    • Fluconazole 200 mg daily for at least 1 year 1, 4
    • Can discontinue maintenance therapy if CD4 count ≥100 cells/μL and undetectable viral load for ≥3 months with minimum of 1 year of antifungal therapy 1
  • Antiretroviral Therapy:

    • Initiate 2-10 weeks after starting antifungal treatment to reduce risk of IRIS 1, 2

Non-HIV, Non-Transplant Patients

  • Induction Phase:

    • Amphotericin B deoxycholate (0.7-1.0 mg/kg/day) plus flucytosine (100 mg/kg/day) for 2 weeks 1
    • Alternative: Amphotericin B (0.7-1.0 mg/kg/day) for 4-6 weeks if flucytosine is unavailable 1
  • Consolidation Phase:

    • Fluconazole 400 mg daily for 8-10 weeks 1
  • Maintenance Phase:

    • Optional: Fluconazole 200 mg daily for 6-12 months 1

Transplant Recipients

  • Induction Phase:

    • Liposomal amphotericin B (3-4 mg/kg/day) or ABLC (5 mg/kg/day) plus flucytosine (100 mg/kg/day) for 2 weeks 1
    • Alternative: Lipid formulation of amphotericin B alone for 4-6 weeks 1
  • Consolidation and Maintenance:

    • Fluconazole 400-800 mg daily for 8 weeks, then 200-400 mg daily for 6-12 months 1
    • Consider immunosuppression reduction 1

Management of Complications

Increased Intracranial Pressure

  • Measure opening pressure during initial lumbar puncture 1
  • For pressure >200 mm H₂O, perform daily lumbar punctures to reduce pressure 1, 2
  • Consider CSF shunting for patients who don't tolerate or respond to repeated lumbar punctures 1

Monitoring Treatment Response

  • Perform follow-up lumbar puncture after 2 weeks of treatment to document CSF sterilization 1
  • Patients with positive cultures at 2 weeks may require longer induction therapy 1
  • Monitor renal function, electrolytes, and complete blood counts regularly during amphotericin B therapy 2, 4

Alternative Regimens

  • When amphotericin B cannot be used: Fluconazole (1200 mg daily) plus flucytosine (100 mg/kg/day) 2, 5
  • When flucytosine is unavailable: Amphotericin B plus fluconazole (400-800 mg daily) 2
  • Recent evidence suggests single high-dose liposomal amphotericin B (10 mg/kg) plus 14 days of flucytosine and fluconazole may be non-inferior to standard therapy with fewer adverse events 6

Common Pitfalls and Caveats

  • Failure to test for HIV in patients with cryptococcal meningitis 1, 2
  • Inadequate management of increased intracranial pressure, which is associated with high mortality 1, 2
  • Premature initiation of antiretroviral therapy in HIV patients (should wait 2-10 weeks) 1, 2
  • Failure to monitor for drug toxicities, especially with amphotericin B (renal toxicity) and flucytosine (bone marrow suppression) 2, 4
  • Relying solely on cryptococcal antigen titers to guide treatment decisions 2, 4
  • Difficulty distinguishing between treatment failure and immune reconstitution inflammatory syndrome (IRIS) if symptoms worsen during or after treatment 1, 2

Dosage Adjustments

  • For flucytosine, monitor serum levels (target: 30-80 μg/mL) and adjust dose based on renal function 1
  • For fluconazole in renal impairment: If creatinine clearance ≤50 mL/min, reduce dose by 50%; for hemodialysis patients, give 100% of dose after each dialysis 3
  • For pediatric patients: Fluconazole 12 mg/kg on first day, then 6 mg/kg daily for cryptococcal meningitis 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Cryptococcal Meningitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Cryptococcosis in Immunocompromised Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.

Current neurology and neuroscience reports, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.